Open AccessDose escalation of an Evans blue–modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors
Author(s) -
Qingxing Liu,
Yuejuan Cheng,
Jie Zang,
Huimin Sui,
Hao Wang,
Orit Jacobson,
Zhaohui Zhu,
Xiaoyuan Chen
Publication year - 2019
Publication title -
european journal of nuclear medicine and molecular imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.313
H-Index - 163
eISSN - 1619-7089
pISSN - 1619-7070
DOI - 10.1007/s00259-019-04530-1
Subject(s) - medicine , neuroendocrine tumors , radionuclide therapy , nuclear medicine , somatostatin , octreotide , adverse effect , chemotherapy , response evaluation criteria in solid tumors , dota , urology , gastroenterology , progressive disease , chelation , chemistry , organic chemistry
To evaluate the safety and efficacy of 177 Lu-DOTA-EB-TATE, a radiolabeled somatostatin analog modified by Evans blue, at escalating doses, was used to increase tumor retention in patients with progressive metastatic neuroendocrine tumors (NETs).